InflaRx N.V. (IFRX)
$1.48-4.52%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $107M
- Beta
- 2.61
- P/E (TTM)
- -2.70
- Short % float
- 22.28%
- Days to cover
- 26.6
- SI change
- +2.1%
- 1W
- -5.13%
- 1M
- -26.73%
- vs SPY 1W
- -4.15%
- vs SPY 1M
- -28.60%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 26
- VALUE
- 11
- GROWTH
- 77
- GARP
- 11
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-34.8%
REV YoY-
ROE-58.0%
EPS YoY-
ROA-23.5%
GROSS48202
OP362271
NET387532
[VALUATION]
P/E TTM-2.70
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.06
P/FCF-
EV/EBITDA-1.27
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.57
ALTMAN Z-
CURR RATIO8.22
ND/EBITDA-
BETA2.61
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR1.1
TRADES44
[REGIME]FULL HISTORY
CRISIS
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on IFRX?
- LOPJLB’s latest quantitative signal on InflaRx N.V. (IFRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IFRX in?
- InflaRx N.V. (IFRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does InflaRx N.V. (IFRX) do?
- InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelim…